Metser, U.; Kohan, A.; O’Brien, C.; Wong, R.K.S.; Ortega, C.; Veit-Haibach, P.; Driscoll, B.; Yeung, I.; Farag, A.
18F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study. Tomography 2024, 10, 1354-1364.
https://doi.org/10.3390/tomography10090102
AMA Style
Metser U, Kohan A, O’Brien C, Wong RKS, Ortega C, Veit-Haibach P, Driscoll B, Yeung I, Farag A.
18F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study. Tomography. 2024; 10(9):1354-1364.
https://doi.org/10.3390/tomography10090102
Chicago/Turabian Style
Metser, Ur, Andres Kohan, Catherine O’Brien, Rebecca K. S. Wong, Claudia Ortega, Patrick Veit-Haibach, Brandon Driscoll, Ivan Yeung, and Adam Farag.
2024. "18F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study" Tomography 10, no. 9: 1354-1364.
https://doi.org/10.3390/tomography10090102
APA Style
Metser, U., Kohan, A., O’Brien, C., Wong, R. K. S., Ortega, C., Veit-Haibach, P., Driscoll, B., Yeung, I., & Farag, A.
(2024). 18F-Fluoroazomycin Arabinoside (FAZA) PET/MR as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study. Tomography, 10(9), 1354-1364.
https://doi.org/10.3390/tomography10090102
